The innovation director has become a border post. You carry the R&D strategy, negotiate with marketing, defend trade-offs in front of the executive committee, sometimes pitch to investors. But between the end of the lab and the start of the market, one piece of work is missing — turning scientific evidence into a marketable narrative. That work is neither marketing nor R&D. It's a discipline of its own.
You will recognise them. They come with the role, not the people.
Internal communication between R&D and marketing is tense, asymmetric, sometimes confrontational. You speak mechanism of action; they speak consumer insight. You speak RCT; they speak claim. Nobody arbitrates.
Your publications land on PubMed servers and locked intranets. Not in the hands of sales, not in press pitches, not in LLM searches. Three years of work invisible at 90%.
You cut six projects out of eight. Nobody knows why the two retained were retained. Innovation isn't narrated — so the committee doubts, investment wavers, and the pipeline is questioned every quarter.
Turn your R&D roadmap — often a 40-row Excel sheet — into a readable narrative for the executive committee and investors. Background brief, master visualisation, 12-slide deck. Annual rebuild, quarterly updates.
Every RCT, meta-analysis, proof-of-concept becomes a signed article, a press angle, a sales sheet, a long-form LinkedIn post — within four weeks of publication. Calendar coordinated with your scientific team.
Monthly translation workshop between your two teams, run by Nicolas Rousseau, who did the job in-house for eighteen years. No coaching, no team-building. Structured working meetings with a deliverable per session.
Your work appears in ChatGPT, Claude, Perplexity, Gemini answers when a formulator, buyer or journalist searches your innovation category. Initial audit, semantic structuring, quarterly measurement.
Average pattern measured across the eight active Innovation/R&D retainers in 2025–2026.
Establishing scientific leadership in hyaluronic-acid fermentation. Lever: thought leadership — fermentation performance is decided upstream, in the nutrients. Pillar deliverable: strategic e-book "Ferment smarter, scale faster", declined by market (cosmetics, nutra, pharma). Impact: the conversation moves from nutrient price to its effect on yield and cost per kilo of HA.
I wrote more than 5,000 health and nutrition articles before switching to the brand side. What separates content that informs from content that moves a buyer: rarely the budget, almost always the angle. Nicolas Rousseau · Nutritionist by training
No. Every claim stays traceable — named clinical study, indexed journal, cited consensus. Source-first principle: a university nutritionist must be able to verify everything in under five minutes.
About one hour per week during the production phase, plus legal and regulatory validation within five business days. The rest of the work lives with us.
A well-structured RCT becomes an asset reusable across some fifteen channels: white paper, conference poster (HiE, Vitafoods, IFT), commercial abstracts per application, sales brief, content citable by ChatGPT and Perplexity.
Never. The strategy phase requires cross-validation by leadership + R&D + sales, and no content ships without double scientific and legal validation.
The world’s second-largest nutraceuticals market, worth USD 17 billion, with 51 per cent of Q3 sales made online: ‘Made in the EU’ is opening the door to the Chinese market. The label alone is not enough to win over consumers.
In brief — The FDA wants to make GRAS notifications, currently voluntary, mandatory. A fragile legal basis since the Loper Bright ruling (2024): what ingredient suppliers targeting the United States are risking.
In brief — Substituting 20% of a chickpea-teff base with carob flour raises fibre by 51%, cuts starch digestibility by 28% and lifts post-cooking firmness from 3.08 N to 4.83 N (Frontiers in Nutrition, 2026).
